European Corporate Strategy

Gilead Sciences and Lakefront Biotherapeutics have closed their joint acquisition of Ouro Medicines, with the Ouro portfolio set to anchor Lakefront's R&D pipeline. Lakefront retains approximately €2 billion in deployable capital, including at least $500 million it can deploy independently of Gilead. The deal positions the former Galapagos as an active European consolidator as incumbents face patent cliffs and next-generation hematology platforms near commercialization.

European corporations are executing major financial restructuring in Q1 2026, led by Eutelsat's €1.5 billion debt refinancing and EP Group's takeover bid for French retailer Fnac Darty. The wave reflects cross-border consolidation and balance sheet optimization as companies leverage strong cash flows despite tariff uncertainties.

French reinsurer SCOR is replacing its CFO and installing new leadership in its Life & Health division while preparing to announce a strategic plan in December 2026. The executive shuffle comes as European insurance firms navigate capital allocation pressures, with peers like Fairfax Financial raising C$650 million in senior notes.